The in vitro antibacterial activities of YM-13115, a new parenteral cephalosporin, were compared with those of ceftazidime, cefoperazone, and cefsulodin. The compound was highly active against the common members of the Enterobacteriaceae and 2 to 256 times more active than cefoperazone. YM-13115 
by an agar plate dilution method with Mueller-Hinton agar (Difco Laboratories, Detroit, Mich.). This medium was supplemented with 5% defibrinated horse blood (in studies with S. pyogenes and S. pneumoniae) and with chocolate agar (in studies with H. influenzae).
With the exception of S. pyogenes, S. pneumoniae, H. influenzae, and P. aeruginosa, inocula were YM-13115 was the most active of the drugs tested against E. coli, K. pneumoniae, E. cloacae, E. aerogenes, S. marcescens, P. mirabilis, P. rettgeri, P. stuartii, and P. aeruginosa. As measured by the concentration required to inhibit the growth of 90% of the isolates, YM-13115 was twoto fourfold more active than ceftazidime against E. coli, K. pneumoniae, E. aerogenes, P. mirabilis, P. rettgeri, and P. aeruginosa. YM-13115 inhibited 100% of the E. cloacae isolates at a concentration of 12.5 ,ug/ml and was at least 16-fold more effective than ceftazidime, cefoperazone, and cefsulodin. A total of 73% of the S. marcescens isolates were inhibited by 0.78 F±g of YM-13115 per ml, whereas ceftazidime inhibited 50% at the same concentration. Cefoperazone and cefsulodin showed little or no activity against this organism. A total of 50% of the P. stuartii isolates were susceptible to 0.025 ,ug of YM-13115 per ml, which was eightfold more active than ceftazidime and 64-fold more active than cefoperazone. YM-13115 also had potent activity against M. morganii and P. vulgaris; the compound was as active as ceftazidime and considerably more active than cefoperazone and cefsulodin. Against H. influenzae, YM-13115 and cefoperazone exhibited nearly equal activities, inhibiting 50 and 90% of the isolates tested at 0.013 and 0.05 p.g/ml, respectively.
In contrast, YM-13115 was less active than the other antibiotics against S. aureus and S. epidermidis. Like ceftazidime and cefsulodin, YM-13115 failed to inhibit S. faecalis. However, all of the S. pyogenes isolates tested were inhibited by 0.78 ,g of YM-13115 per ml, and 89% of the S. pneurnoniae isolates were inhibited by this concentration. Against S. pyogenes and S. pneumoniae, the activity of YM-13115 was lower than those of ceftazidime and cefoperazone but higher than that of cefsulodin.
Killing curves. Killing curve studies were performed with YM-13115 and ceftazidime against representative strains of E. coli (Fig. 2) and P. aeruginosa (Fig. 3) . When (12) . The compound was also resistant to hydrolysis by common chromosomal cephalosporinases produced by C. freundii (15) , E. cloacae (9), P. aeruginosa (10), P. vulgaris (7), and P. cepacia (4 (3, 6, 11, 17, 18) , namely, in vitro activity at very low concentrations against a very wide variety of gram-negative organisms and high stability against P-lactamases. This study demonstrates that YM-13115 has enhanced activity against gram-negative bacteria and is substantially more active against all members of the Enterobacteriaceae (including known 1-lactamase producers) than ceftazidime, cefoperazone, and cefsulodin. A further advan- tage of YM-13115 over ceftazidime, cefsulodin, and other broad-spectrum cephalosporins (3, 11, 18 ) is its extremely high activity against P. aeruginosa. Indeed, it is the most effective and most reliable antibiotic against this species, with 90% of the isolates inhibited by YM-13115 at 3.13 ,ug/ml. Also, killing curve studies with P. aeruginosa indicated that concentrations greater than one-half the MIC (0.39 pg/ml) of YM-13115 result in a similar reduction in the numbers of viable bacteria. The mechanism of the absence of a response to various concentrations of YM-13115 is difficult to deduce from this study. The MBCs of YM-13115 usually were within a twofold dilution of the MICs. The low MBCs may be related to the great r-lactamase stability of this compound. Organisms such as S. marcescens, P. aeruginosa, and others are the cause of many episodes of severe infections usually acquired in the hospital. The exceptional activity of YM-13115 and additional characteristics, such as its bactericidal activity and stability against 1-lactamases, suggest that it should be a highly effective therapeutic agent, particularly in the treatment of hospital-acquired infections. On the other hand, in an animal pharmacokinetic study, Matsui et al. reported that YM-13115 was a long-acting cephalosporin with a plasma half-life of 5.30 h in monkeys, as compared with 3.40 h for ceftriaxone (8) . YM-13115 is a promising new agent which deserves clinical testing in the future.
